Calquence Combination Therapy Reduces Disease Progression or Death Risk by 27% in Phase III Trial

A recent phase III trial indicates that a combination therapy using Calquence, bendamustine, and rituximab demonstrated a reduction in the risk of disease progression or death. The trial compared this combination against the current standard of care for the patient population studied. Specifically, researchers found that the Calquence-based regimen reduced the risk of disease progression or death by 27% when compared to the existing standard treatment. The study’s findings suggest a potential alternative approach to current treatments, but further analysis and review are needed to fully understand the implications of these results.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Author

Mark Chiang